Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
AXGN Stock Chart & Stats
$31.98
>-$0.01(>-0.01%)
At close: 4:00 PM EST
$31.98
>-$0.01(>-0.01%)
Day’s Range― - ―
52-Week Range$9.22 - $34.24
Previous CloseN/A
Volume66.42K
Average Volume (3M)890.39K
Market Cap
$1.47B
Enterprise Value$903.86M
Total Cash (Recent Filing)$35.79M
Total Debt (Recent Filing)$67.91M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 03, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding46,122,288
10 Day Avg. Volume1,190,094
30 Day Avg. Volume890,389
Financial Highlights & Ratios
PEG Ratio1.33
Price to Book (P/B)7.02
Price to Sales (P/S)3.89
P/FCF Ratio66.31K
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue4.21
Enterprise Value/Gross Profit5.63
Enterprise Value/Ebitda42.06
Forecast
1Y Price Target
$37.67Price Target Upside17.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.29
Revenue Forecast (FY)$223.37M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAxogen reported 23.5% year-over-year revenue growth, exceeding projections and demonstrating strong financial performance.
Market ExclusivityAvance has been granted Regenerative Medicine Advance Therapy designation, granting 12 years of exclusivity in the U.S. from commercial competition.
Regulatory ApprovalFDA approval for Avance as a biologic strengthens its market positioning and should facilitate further market penetration.
Bears Say
Government ShutdownThe government shutdown poses risks of FDA delays due to funding issues and potential backlog.
Regulatory ChallengesFDA is requiring confirmatory trials for continued approval in sensory nerve gaps over 25mm and mixed/motor, which may imply future clinical work.
Regulatory DelaysThere is a risk that the government shutdown could delay FDA feedback on product labeling for Avance.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $9.21 and its highest was $34.24 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $1.47B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Mar 03, 2026 which is in 73 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Oct 29, 2025. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.072 by $0.048.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.06.
How many shares outstanding does AxoGen have?
AxoGen has 46,122,288 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, beating expectations of $0.072. Following the earnings report the stock price went up 23.064%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (17.79% Upside)
$37.67 (17.79% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 371.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.8%
Last 30 Days ▲ 30.8%
Last 30 Days ▲ 30.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.05%
12-Months-Change
Fundamentals
Return on Equity
-1.90%
Trailing 12-Months
Asset Growth
12.72%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. is a biotechnology company that specializes in the development and commercialization of innovative surgical solutions for the repair of peripheral nerves. The company operates primarily in the healthcare sector, focusing on nerve repair and regeneration. AxoGen's core products include Avance Nerve Graft, a human acellular nerve allograft, and AxoGuard Nerve Connector, which facilitates the surgical repair of damaged nerves. The company aims to improve patient outcomes in the treatment of nerve injuries resulting from trauma, surgery, or disease.
AXGN Company Deck
AXGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and operational performance across all target markets, driven by increased adoption and positive gross margin trends. However, some challenges were noted in reaching high potential account goals and the extended timeline for BLA approval. Despite these challenges, the overall sentiment is positive, given the robust financial performance and strategic progress.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
Average Price Target
$37.67
▲(17.79% Upside)
Technical Analysis
Ownership Overview
1.76% Insiders
18.77% Mutual Funds
44.63% Other Institutional Investors
21.45% Public Companies and
Individual Investors